"I look forward to hearing what the pioneers in this very important field have to say"
Franklin, TN (PRWEB) October 13, 2016
The 2016 FH Global Summit will take place in Dallas, Texas October 17 & 18. Keynote speakers include Nobel laureates Professors Michael S. Brown and Joseph L. Goldstein. According to the FH Foundation, it is an exclusive invitation-only event that will convene distinguished leaders in diverse fields to change the status quo. With a goal to translate FH research into clinical practice, attendees will represent cardiology, lipidology, biochemistry, health economics, bioinformatics and public health.
- From Genetics to Biology to Novel Therapeutics
- Opportunities and Challenges: Clinical Genetic Testing for FH
- Current Landscape of FH and Identification of Individuals with FH
- Translating Science into Clinical Results: Looking Toward the Future
MyGenetx, an advanced healthcare laboratory, is one of the summit’s corporate supporters. The lab will be exhibiting as well as attending the sessions. The Franklin, Tennessee molecular laboratory offers an extended Next Generation Sequencing panel to help differentiate FH from other forms of hyperlipidemia.
Karen L. Graves, MD, Director of Clinical Studies at MyGenetx, stated, "I am very pleased and excited to be invited to this year’s FH Global Summit. I look forward to hearing what the pioneers in this very important field have to say, and to seeing the spotlight turned on ways to diagnose and treat this very prevalent disease process." MyGenetx Chief Science Officer, David Vigerust, PhD will also be in attendance. Dr. Graves and Dr. Vigerust co-authored “Hp: an inflammatory indicator in cardiovascular disease”, which was published in this year’s July issue of Future Cardiology.
MyGenetx is a CLIA-certified lab focused on molecular and advanced diagnostic testing. MyGenetx is a primary resource for transitioning and implementing precision-guided medicine. The medical team consists of experts in research and clinical product development for genetics.
Familial Hypercholesterolemia (FH) is an inherited disorder that leads to aggressive and premature cardiovascular disease. 1 in 250 people have FH, yet 90% are undiagnosed. To learn more about FH, visit thefhfoundation.org.